Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07244887
PHASE4

Randomized, Triple-Blind, Vehicle-Controlled Trial of Topical Dapsone Gel 7.5% in Patients With Acne Vulgaris

Sponsor: Oya Helin Dundar

View on ClinicalTrials.gov

Summary

The goal of this randomized, triple-blind, vehicle-controlled clinical trial is to evaluate whether topical 7.5% dapsone gel is effective for treating mild-to-moderate acne vulgaris in adults. The main questions are: * Does dapsone gel improve global acne severity compared with a matched vehicle gel? * Does dapsone gel improve comedonal and papulopustular acne severity? * Does dapsone gel reduce erythema and melanin indices measured with a Mexameter, and sebum index measured with a Sebumeter? * Does treatment with dapsone gel improve patients' acne-related quality of life? Researchers compared once-daily dapsone gel with a matched vehicle gel without the active ingredient. Participants: * Applied either dapsone gel or vehicle gel once daily for 8 weeks * Attended clinic visits at baseline, week 4, week 8, and week 12 * Had acne severity assessed using the Global Acne Grading System and Plewig and Kligman comedonal and papulopustular stages * Had erythema and melanin measured with a Mexameter, and sebum measured with a Sebumeter at predefined facial sites * Completed an acne quality-of-life questionnaire at baseline and week 8 * Had standardized photographs taken at each visit Treatment was continued for 8 weeks, followed by a 4-week treatment-free follow-up through week 12.

Official title: Randomized, Triple-Blind, Vehicle-Controlled Trial Evaluating Clinical Efficacy, Sebum, Erythema, Melanin and Quality-of-Life Outcomes of Topical Dapsone Gel 7.5% in Patients With Acne Vulgaris

Key Details

Gender

All

Age Range

18 Years - 50 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2025-06-17

Completion Date

2026-03-01

Last Updated

2026-05-22

Healthy Volunteers

No

Conditions

Interventions

DRUG

Dapsone 7.5% gel

Topical dapsone 7.5% gel applied once daily to the entire face for 8 weeks; route: topical. The study product was supplied in an identical-appearing tube to maintain masking. Participants were followed for 4 weeks after treatment discontinuation.

DRUG

Vehicle gel

Vehicle gel without dapsone, identical in base, tube, and packaging to the active product; applied once daily to the entire face for 8 weeks; route: topical. Participants were followed for 4 weeks after treatment discontinuation.

Locations (1)

Istanbul Training and Research Hospital

Istanbul, Turkey (Türkiye)